Profiling of the fecal microbiota and circulating microRNA-16 in IBS subjects with Blastocystis infection : a case–control study
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the...
Saved in:
Published in | European journal of medical research Vol. 28; no. 1; pp. 1 - 11 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central Ltd
06.11.2023
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
ISSN | 2047-783X 0949-2321 2047-783X |
DOI | 10.1186/s40001-023-01441-8 |
Cover
Loading…
Abstract | Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of
Blastocystis
on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate
Blastocystis
and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes
,
Actinobacteria
, Faecalibacterium,
and
Alistipes
. In IBS patients, the relative abundance of
Bifidobacteria
was directly correlated with the presence of
Blastocystis
, while
Alistipes
was decreased with
Blastocystis
.
Lactobacillus
was significantly increased in
Blastocystis
carriers. In healthy subjects, the relative abundance of
Bifidobacteria
was decreased, but
Alistipes
was increased in
Blastocystis
carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in
Blastocystis
-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of
Blastocystis
, decreased the relative expression of mir-16 in IBS patients compared to
Blastocystis
-negative IBS patients. The present study revealed that
Blastocystis
has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover,
Blastocystis
seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization. |
---|---|
AbstractList | Abstract Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization. Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization. Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystisseems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization. Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes , Actinobacteria , Faecalibacterium, and Alistipes . In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis , while Alistipes was decreased with Blastocystis . Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis -negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis , decreased the relative expression of mir-16 in IBS patients compared to Blastocystis -negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization. Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization. Keywords: IBS, Blastocystis, Fecal microbiota, MicroRNA, mir-16 Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization.Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization. |
ArticleNumber | 483 |
Audience | Academic |
Author | Sadeghi, Amir Mirsamadi, Elnaz Sadat Olyaiee, Alireza Mirjalali, Hamed Yadegar, Abbas |
Author_xml | – sequence: 1 givenname: Alireza surname: Olyaiee fullname: Olyaiee, Alireza – sequence: 2 givenname: Abbas surname: Yadegar fullname: Yadegar, Abbas – sequence: 3 givenname: Elnaz Sadat surname: Mirsamadi fullname: Mirsamadi, Elnaz Sadat – sequence: 4 givenname: Amir surname: Sadeghi fullname: Sadeghi, Amir – sequence: 5 givenname: Hamed surname: Mirjalali fullname: Mirjalali, Hamed |
BookMark | eNp9ks2KFDEQxxtZwXXdF_AUEMRLr0lPOp32IruLHwOLih_gLVSnq2cyZDprJ63MTfARfAGfxUfxSayeWXFnEckhIfnVv1JV_7vZQR96zLL7gp8IodXjKDnnIufFLOdCSpHrW9lhwWWVV3r28eDa-U52HOOKaK4KVdX1YfbtzRA6512_YKFjaYmsQwuerZ0dQuNCAgZ9y6wb7OghTdz26e2r01wo5no2P3vH4tis0KbIvri0ZGceYgp2E5OLRJBgcqH_-eMJA2Yh4q-v323o0xA8i2lsN_ey2x34iMdX-1H24fmz9-cv84vXL-bnpxe5Lasi5dbOZNmWVqqilLVC2iy0ba0VFhoKXopC1C1YXraai7KbVaLjumyxbgAt6tlRNt_ptgFW5nJwaxg2JoAz24swLAwMyVmPRogGu6pTgAqk1Y0uSz2ThVSNQCF5Q1pPd1qXY7PG1iLVA35PdP-ld0uzCJ-N2LZeKlJ4dKUwhE8jxmTWLlr0HnoMYzSF1qqmyVac0Ac30FUYh556RVTNSbKq9F9qAVQB9T1QYjuJmtOqElpOKFEn_6BotUiDJWORG3A_4OG1gCWCT8sY_DjNNO6DegeSPWIcsDPWJZgwyuA8VW4mu5qdXQ3Z1WztaqavFzdC_zTyP0G_AXNf738 |
CitedBy_id | crossref_primary_10_1007_s10238_024_01396_y crossref_primary_10_3390_ijms26010413 crossref_primary_10_3389_fmicb_2025_1540943 |
Cites_doi | 10.1186/s12967-023-03953-7 10.1042/BCJ20160510 10.1016/j.mce.2022.111572 10.1111/1462-2920.14271 10.1186/s40168-016-0191-0 10.1097/MD.0000000000014513 10.7150/thno.81583 10.3389/fmed.2022.940332 10.1186/s40168-015-0139-9 10.1371/journal.ppat.1009253 10.1016/j.semcdb.2023.01.009 10.1053/j.gastro.2016.09.049 10.3390/jcm8111808 10.1186/s40168-019-0704-8 10.3390/microorganisms10020326 10.1128/Spectrum.00484-21 10.1186/1471-2164-14-788 10.3389/fmicb.2023.1147945 10.1016/j.mimet.2011.06.010 10.5009/gnl19379 10.1007/s00436-012-2830-0 10.1128/AEM.05605-11 10.3906/sag-2002-57 10.5217/ir.2015.13.1.11 10.3389/fmicb.2018.01600 10.1371/journal.pone.0015484 10.7150/ijbs.45885 10.1016/j.jbc.2022.102461 10.3390/jpm11010035 10.1038/s41575-019-0157-3 10.1186/s12876-021-01693-w 10.1186/s12866-022-02528-8 10.3389/fimmu.2020.00906 10.1053/j.gastro.2011.07.043 10.1007/s00018-022-04271-9 10.1186/s12866-021-02341-9 10.1172/JCI130976 10.1038/s41591-020-01183-8 10.3389/fmed.2022.890127 10.2166/wh.2021.011 10.3390/microorganisms10010034 10.3920/BM2012.0018 10.1152/ajpgi.00154.2011 10.5056/jnm22093 10.1186/s13071-015-1069-x 10.1159/000477205 10.1111/j.1462-5822.2012.01814.x 10.3390/nu12041096 10.1016/j.ebiom.2019.11.023 10.1136/gutjnl-2016-311477 10.3390/toxins13110758 10.1128/mSystems.00007-18 10.1038/ismej.2017.139 10.1016/j.mehy.2018.04.006 10.1038/s41396-022-01262-3 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023. The Author(s). The Author(s) 2023 |
Copyright_xml | – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023. The Author(s). – notice: The Author(s) 2023 |
DBID | AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
DOI | 10.1186/s40001-023-01441-8 |
DatabaseName | CrossRef ProQuest Central (Corporate) Proquest Health & Medical Complete ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ (Directory of Open Access Journals) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2047-783X |
EndPage | 11 |
ExternalDocumentID | oai_doaj_org_article_11bef7f6ae6a4c8b855834246b1e140b PMC10626746 A771848901 10_1186_s40001_023_01441_8 |
GeographicLocations | Iran Germany |
GeographicLocations_xml | – name: Iran – name: Germany |
GroupedDBID | --- 0R~ 4.4 53G 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABUWG ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION DIK EBD EBLON EBS EMOBN F5P FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 UKHRP PMFND 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c572t-cc345d5c4625496e625cadd986e28a2051219dac05d8015f371f085de9baece83 |
IEDL.DBID | M48 |
ISSN | 2047-783X 0949-2321 |
IngestDate | Wed Aug 27 00:47:14 EDT 2025 Thu Aug 21 18:36:13 EDT 2025 Fri Jul 11 10:41:09 EDT 2025 Sat Jul 26 02:33:46 EDT 2025 Tue Jun 17 22:23:17 EDT 2025 Tue Jun 10 21:17:14 EDT 2025 Thu May 22 21:20:02 EDT 2025 Thu Apr 24 22:56:06 EDT 2025 Tue Jul 01 02:25:18 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c572t-cc345d5c4625496e625cadd986e28a2051219dac05d8015f371f085de9baece83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s40001-023-01441-8 |
PQID | 2890106778 |
PQPubID | 2040181 |
PageCount | 11 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_11bef7f6ae6a4c8b855834246b1e140b pubmedcentral_primary_oai_pubmedcentral_nih_gov_10626746 proquest_miscellaneous_2886940070 proquest_journals_2890106778 gale_infotracmisc_A771848901 gale_infotracacademiconefile_A771848901 gale_healthsolutions_A771848901 crossref_citationtrail_10_1186_s40001_023_01441_8 crossref_primary_10_1186_s40001_023_01441_8 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-11-06 |
PublicationDateYYYYMMDD | 2023-11-06 |
PublicationDate_xml | – month: 11 year: 2023 text: 2023-11-06 day: 06 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | European journal of medical research |
PublicationYear | 2023 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | LR Lopetuso (1441_CR43) 2018; 36 M Norouzi (1441_CR22) 2022; 9 I-K Wang (1441_CR30) 2012; 78 Q Sun (1441_CR50) 2019; 98 L Deng (1441_CR53) 2023; 13 C Martínez (1441_CR21) 2017; 66 V Shankar (1441_CR9) 2015; 3 S Cifre (1441_CR13) 2018; 116 F Asnicar (1441_CR16) 2021; 27 L Mei (1441_CR2) 2021; 21 A Gasbarrini (1441_CR7) 2008; 12 M Rajilić-Stojanović (1441_CR8) 2011; 141 S Nemati (1441_CR12) 2021; 19 M Moszak (1441_CR25) 2020; 12 LK Vigsnæs (1441_CR32) 2012; 3 BJ Parker (1441_CR46) 2020; 11 SH Lee (1441_CR57) 2015; 13 F Beghini (1441_CR15) 2017; 11 N Springham (1441_CR28) 2015; 4 MJ Kozieł (1441_CR58) 2021; 13 MH Ismail (1441_CR39) 2022; 68 PH Johnsen (1441_CR3) 2020; 51 SM Lee (1441_CR42) 2021; 15 G Gargari (1441_CR51) 2018; 20 L Zhao (1441_CR6) 2020; 130 L Deng (1441_CR35) 2021; 17 IM Carroll (1441_CR45) 2011; 301 F Dogruman-Al (1441_CR14) 2010; 5 ML Hermann-Bank (1441_CR27) 2013; 14 I Schoultz (1441_CR56) 1909; 2020 S Fagoonee (1441_CR10) 2019; 8 B Dalile (1441_CR52) 2019; 16 K Oliphant (1441_CR48) 2019; 7 TB De Gregoris (1441_CR24) 2011; 86 H Mirza (1441_CR18) 2012; 14 H Mohammad Rahimi (1441_CR19) 2022; 22 S Keshavarz Azizi Raftar (1441_CR29) 2021; 9 W Jiang (1441_CR49) 2022; 28 ZA Barandouzi (1441_CR44) 2021; 11 A Olivo-Diaz (1441_CR38) 2012; 111 EM Quigley (1441_CR31) 2013; 9 H Chen (1441_CR41) 2023; 21 KJ O'Riordan (1441_CR47) 2022; 546 E Thursby (1441_CR26) 2017; 474 MJ Kim (1441_CR36) 2021; 10 X Zhuang (1441_CR34) 2018; 9 R Nagel (1441_CR4) 2016; 4 M Xi (1441_CR60) 2022; 298 R Nagel (1441_CR40) 2015; 8 A Olyaiee (1441_CR1) 2022; 9 CR Stensvold (1441_CR37) 2022; 10 FS Gholam-Mostafaei (1441_CR23) 2023; 14 M Nieves-Ramírez (1441_CR11) 2018; 3 J Tap (1441_CR33) 2017; 152 J Mayneris-Perxachs (1441_CR55) 2022; 16 L Deng (1441_CR54) 2022; 79 X Zhao (1441_CR59) 2021; 17 HF Dale (1441_CR5) 2020; 50 1441_CR20 SA Karamati (1441_CR17) 2021; 21 |
References_xml | – volume: 21 start-page: 117 year: 2023 ident: 1441_CR41 publication-title: J Transl Med doi: 10.1186/s12967-023-03953-7 – volume: 474 start-page: 1823 year: 2017 ident: 1441_CR26 publication-title: Biochem J doi: 10.1042/BCJ20160510 – volume: 546 year: 2022 ident: 1441_CR47 publication-title: Mol Cell Endocrinol doi: 10.1016/j.mce.2022.111572 – volume: 20 start-page: 3201 year: 2018 ident: 1441_CR51 publication-title: Environ Microbiol doi: 10.1111/1462-2920.14271 – volume: 4 start-page: 47 year: 2016 ident: 1441_CR4 publication-title: Microbiome doi: 10.1186/s40168-016-0191-0 – volume: 98 year: 2019 ident: 1441_CR50 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000014513 – volume: 13 start-page: 1165 year: 2023 ident: 1441_CR53 publication-title: Theranostics doi: 10.7150/thno.81583 – volume: 9 year: 2022 ident: 1441_CR22 publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2022.940332 – volume: 3 start-page: 73 year: 2015 ident: 1441_CR9 publication-title: Microbiome doi: 10.1186/s40168-015-0139-9 – volume: 17 year: 2021 ident: 1441_CR35 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1009253 – ident: 1441_CR20 doi: 10.1016/j.semcdb.2023.01.009 – volume: 152 start-page: 111 year: 2017 ident: 1441_CR33 publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.09.049 – volume: 8 start-page: 1808 year: 2019 ident: 1441_CR10 publication-title: J Clin Med doi: 10.3390/jcm8111808 – volume: 7 start-page: 91 year: 2019 ident: 1441_CR48 publication-title: Microbiome doi: 10.1186/s40168-019-0704-8 – volume: 10 start-page: 326 year: 2022 ident: 1441_CR37 publication-title: Microorganisms doi: 10.3390/microorganisms10020326 – volume: 9 start-page: e00484 year: 2021 ident: 1441_CR29 publication-title: Microbiol Spect doi: 10.1128/Spectrum.00484-21 – volume: 4 issue: u209153 year: 2015 ident: 1441_CR28 publication-title: BMJ Open Qual – volume: 14 start-page: 1 year: 2013 ident: 1441_CR27 publication-title: BMC Genomic doi: 10.1186/1471-2164-14-788 – volume: 14 start-page: 499 year: 2023 ident: 1441_CR23 publication-title: Front Microbiol doi: 10.3389/fmicb.2023.1147945 – volume: 86 start-page: 351 year: 2011 ident: 1441_CR24 publication-title: J Microbiol Method doi: 10.1016/j.mimet.2011.06.010 – volume: 15 start-page: 253 year: 2021 ident: 1441_CR42 publication-title: Gut Liver doi: 10.5009/gnl19379 – volume: 111 start-page: 487 year: 2012 ident: 1441_CR38 publication-title: Parasitol Res doi: 10.1007/s00436-012-2830-0 – volume: 78 start-page: 1107 year: 2012 ident: 1441_CR30 publication-title: Appl Environ Microbiol doi: 10.1128/AEM.05605-11 – volume: 50 start-page: 1632 year: 2020 ident: 1441_CR5 publication-title: Turk J Med Sci doi: 10.3906/sag-2002-57 – volume: 13 start-page: 11 year: 2015 ident: 1441_CR57 publication-title: Intestin Res doi: 10.5217/ir.2015.13.1.11 – volume: 9 start-page: 1600 year: 2018 ident: 1441_CR34 publication-title: Front Microbiol doi: 10.3389/fmicb.2018.01600 – volume: 5 year: 2010 ident: 1441_CR14 publication-title: Turkey PLoS One doi: 10.1371/journal.pone.0015484 – volume: 2020 start-page: 9 year: 1909 ident: 1441_CR56 publication-title: Cells – volume: 17 start-page: 712 year: 2021 ident: 1441_CR59 publication-title: Int J Biol Sci doi: 10.7150/ijbs.45885 – volume: 298 issue: 11 year: 2022 ident: 1441_CR60 publication-title: J Biol Chem doi: 10.1016/j.jbc.2022.102461 – volume: 11 start-page: 35 year: 2021 ident: 1441_CR44 publication-title: J Pers Med doi: 10.3390/jpm11010035 – volume: 16 start-page: 461 year: 2019 ident: 1441_CR52 publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/s41575-019-0157-3 – volume: 21 start-page: 105 year: 2021 ident: 1441_CR2 publication-title: BMC Gastroenterol doi: 10.1186/s12876-021-01693-w – volume: 22 start-page: 111 year: 2022 ident: 1441_CR19 publication-title: BMC Microbiol doi: 10.1186/s12866-022-02528-8 – volume: 11 start-page: 906 year: 2020 ident: 1441_CR46 publication-title: Front Immunol doi: 10.3389/fimmu.2020.00906 – volume: 141 start-page: 1792 year: 2011 ident: 1441_CR8 publication-title: Gastroenterology doi: 10.1053/j.gastro.2011.07.043 – volume: 79 start-page: 245 year: 2022 ident: 1441_CR54 publication-title: Cell Mol Life Sci doi: 10.1007/s00018-022-04271-9 – volume: 21 start-page: 285 year: 2021 ident: 1441_CR17 publication-title: BMC Microbiol doi: 10.1186/s12866-021-02341-9 – volume: 130 start-page: 438 year: 2020 ident: 1441_CR6 publication-title: J Clin Invest doi: 10.1172/JCI130976 – volume: 27 start-page: 321 year: 2021 ident: 1441_CR16 publication-title: Nat Med doi: 10.1038/s41591-020-01183-8 – volume: 9 year: 2022 ident: 1441_CR1 publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2022.890127 – volume: 19 start-page: 687 year: 2021 ident: 1441_CR12 publication-title: J Water Health doi: 10.2166/wh.2021.011 – volume: 10 start-page: 34 year: 2021 ident: 1441_CR36 publication-title: Microorganisms doi: 10.3390/microorganisms10010034 – volume: 3 start-page: 287 year: 2012 ident: 1441_CR32 publication-title: Beneficial Microb doi: 10.3920/BM2012.0018 – volume: 301 start-page: G799 year: 2011 ident: 1441_CR45 publication-title: Am J Physiol Gastrointest Liver Physiol doi: 10.1152/ajpgi.00154.2011 – volume: 28 start-page: 540 year: 2022 ident: 1441_CR49 publication-title: J Neurogastroenterol Motil doi: 10.5056/jnm22093 – volume: 8 start-page: 453 year: 2015 ident: 1441_CR40 publication-title: Parasit Vectors doi: 10.1186/s13071-015-1069-x – volume: 36 start-page: 56 year: 2018 ident: 1441_CR43 publication-title: Dig Dis doi: 10.1159/000477205 – volume: 14 start-page: 1474 year: 2012 ident: 1441_CR18 publication-title: Cell Microbiol doi: 10.1111/j.1462-5822.2012.01814.x – volume: 12 start-page: 1096 year: 2020 ident: 1441_CR25 publication-title: Nutrients doi: 10.3390/nu12041096 – volume: 51 year: 2020 ident: 1441_CR3 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2019.11.023 – volume: 66 start-page: 1537 year: 2017 ident: 1441_CR21 publication-title: Gut doi: 10.1136/gutjnl-2016-311477 – volume: 13 start-page: 758 year: 2021 ident: 1441_CR58 publication-title: Toxins doi: 10.3390/toxins13110758 – volume: 3 start-page: e00007 year: 2018 ident: 1441_CR11 publication-title: Msystems doi: 10.1128/mSystems.00007-18 – volume: 11 start-page: 2848 year: 2017 ident: 1441_CR15 publication-title: ISME J doi: 10.1038/ismej.2017.139 – volume: 116 start-page: 4 year: 2018 ident: 1441_CR13 publication-title: Med Hypotheses doi: 10.1016/j.mehy.2018.04.006 – volume: 9 start-page: 560 year: 2013 ident: 1441_CR31 publication-title: Gastroenterol Hepatol – volume: 68 start-page: 77 year: 2022 ident: 1441_CR39 publication-title: Ann Parasitol – volume: 12 start-page: 111 issue: Suppl 1 year: 2008 ident: 1441_CR7 publication-title: Eur Rev Med Pharmacol Sci – volume: 16 start-page: 2181 year: 2022 ident: 1441_CR55 publication-title: Isme J doi: 10.1038/s41396-022-01262-3 |
SSID | ssj0000626799 |
Score | 2.3557289 |
Snippet | Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between... Abstract Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction... |
SourceID | doaj pubmedcentral proquest gale crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 1 |
SubjectTerms | Bacteria Blastocystis Consent Digestive system Fecal microbiota Gastroenterology Guardians Health aspects IBS Irritable bowel syndrome Medical research Medicine, Experimental Microbiota Microbiota (Symbiotic organisms) Microorganisms MicroRNA MicroRNAs mir-16 Proteins |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NatVAFB6ki-JGtCpGax1BcCGh-ZmZnLi7VyxVaBG10N0wf8ELmitN7sJdoY_gC_gsPopP0nMmuZcbBd24CmROIHP-Z-bMdxh7FmwNtlQibarKpQJ8SK0DldYqlBhSDITYee7kVB2fibfn8nyr1RfVhA3wwAPjDvPchqZqlAnKCAcWpIRSFELZPODiwJL3xZi3tZgafHChqrpe35IBddiJLFYPFVQ-hDlACpNIFAH7_3TLv5dKbsWeo9vs1pg08tnws3fYjdDusd2T8Vj8Lrt6FztvYxTiy4ZjSsebgLznXxYDzFJvuGk9d4sLF7t1IV0cen86S3PFFy1_M__Au5WlTZmO094sn2Na3S_dN3QBHV-XbLU_f7zkhjsMfb8uv49l7jxC1N5jZ0evP746TsfuCqmTVdGnzpVCeumEojWiCvhw6OxqUKEAU6CxojPzxmXSYxSTTVnlDeZnPtTWBBegvM922mUbHjDuc2GkCxnUGQgvvRWegMAolWmKAnzC8jWntRuhx6kDxmcdlyCg9CAdjdLRUToaEvZi883XAXjjr9RzEuCGkkCz4wtUJT2qkv6XKiXsCYlfDzdQN6avZxUGcIGTyxP2PFKQ8eMEnBnvMCAbCEZrQrk_oUSjddPhtYrp0Wl0ms58B0S_hD3dDNOXVAjXhuWKaEDFXvZZwmCimpO5T0faxacIHJ5HsxDq4f_g1iN2syBroi12tc92-otVeIwJWm8Poi1eA876OH4 priority: 102 providerName: Directory of Open Access Journals – databaseName: Proquest Health & Medical Complete dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fi9QwEA96gvgi_sXqqREEHyTctk3T1BfZFY9TuEPUg30L-ddzQdtz233wTfwKfkM_iTNpWq3CPS00E5Z2MjO_TCa_IeSpN5U0ueCsLkvLuHSeGSsFq4TPIaRo6UPnueMTcXTK366LdUy4dbGscvSJwVG71mKO_AAPxAa6s5fnXxl2jcLT1dhC4zK5gtRluPkq1-WUY1kAWi-rgW6PVwzAQzrem5HioOOLUE-UYUERoAImZ7EpUPj_76j_LZ78Kxod3iDXI4yky0HvN8kl39wiV4_jQflt8uNd6MUNcYm2NQWQR2sP2qBfNgPxUq-pbhy1m60N_btALgy9P1myVNBNQ9-sPtBuZzBN01HM1tIVAO2-td_AKXR0LOJq6AuqqYVY-Ov7z1j3TgNn7R1yevj646sjFtstMFuUWc-szXnhCssFbhqFhx8L3q-SwmdSZ2C94N2ctovCQVgr6rxMawBszldGe-tlfpfsNW3j7xHqUq4L6xegM8ld4Qx3yAyG2KbOMukSko4fWtnIRY4tMT6rsCeRQg3KUaAcFZSjZEKeT3POByaOC6VXqL9JElm0w4N2e6aiUcJc4-uyFtoLza00sihkzjMuTOph42kS8hi1r4YrqZMvUMsSIjrHBZmQZ0ECvQG8gNXxUgN8BuTVmknuzyTBiu18eFxhKnqRTv1Z8wl5Mg3jTKyMa3y7QxkpQnP7RULkbGXO3n0-0mw-BSbxNFgIF_cv_vcH5FqGZoLZdLFP9vrtzj8ELNabR8HgfgPBHzCX priority: 102 providerName: ProQuest |
Title | Profiling of the fecal microbiota and circulating microRNA-16 in IBS subjects with Blastocystis infection : a case–control study |
URI | https://www.proquest.com/docview/2890106778 https://www.proquest.com/docview/2886940070 https://pubmed.ncbi.nlm.nih.gov/PMC10626746 https://doaj.org/article/11bef7f6ae6a4c8b855834246b1e140b |
Volume | 28 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9QwFA57AfFFvGJ1HSMIPkh12qZJRhCZkV3WgRmWXQfmLeRWHVhbnQu4b4I_wT_gb_Gn-Es8J20Hq4vgU6E5KSQn55L05PsIeezNQJqMs7gQwsZMOh8bK3k84D6DkKKlD8xzkyk_nrHxPJ_vkJbuqJnA1aVbO-STmi3Pn33-dPEKDP5lMHjJn69YPxQGpVgZBOE9lrtkHyKTQCqHSZPu15455SJQSqYIUCBkNm_v0Vz6mU6sCpD-fzvuP4spf4tOR9fJtSatpMN6HdwgO768Sa5Mmh_nt8jXk8DNDXGKVgWFpI8WHrRDPyxqIKa1prp01C6WNvB5gVxoOp0O44TTRUnfjM7oamPw2GZF8fSWjiDxXlf2ApzEirZFXeWP7y-ophaC488v35pCeBpAbG-T2dHh29fHccO_ENtcpOvY2ozlLreM4y6Se3hYcIcDyX0qdQrmDO7OadvPHcS5vMhEUkAG5_zAaG-9zO6QvbIq_V1CXcJ0bn1fDvqSudwZ5hAqDJOdIk2li0jSzrSyDTg5cmScq7BJkVzV2lGgHRW0o2REnm77fKyhOf4pPUIFbiURVju8qJbvVGOl0Nf4QhRce66ZlUbmucxYyrhJPOxETUQeovpVfUd16xzUUECIZzC4JCJPggQuWBiA1c0tB5gGBNrqSB50JMGsbbe5XWKqtQqFf4VrzL-IPNo2Y08slSt9tUEZyQPbfT8isrM0O2PvtpSL9wFaPAkmwvi9_5rb--RqimaDp-38gOytlxv_AHK1temRXTEXPbI_HI7PxvAcHU5PTnvh5KMXjPMX-_Y9yQ |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VIgEXxK8wFLpIIA7Iamyv12skhBKgSmgTIWil3rb7Z4gEdokTod4Qr8B78FA8CTNrO2CQeuspUnY2kT3_s7PfEPLI6VzohLOwyDITMmFdqI3gYc5dAi5FCecnz01nfHzI3hylRxvkZ3cXBtsqO5voDbWtDNbId_BArIE7e3HyJcSpUXi62o3QaMRiz51-hZStfj55Bfx9HMe7rw9ejsN2qkBo0ixehsYkLLWpYRxzI-7gw4CS54K7WKgYhBSU2CozSC1Y77RIsqiAuMS6XCtnnEjgdy-Qi-B4B9hCmB1l65rOALKDLG_g_VgeQrASdfd0BN-p2cD3L8XYwARRSCh6vtCPDPjfMfzbrPmX99u9Rq62YSsdNnJ2nWy48ga5NG0P5m-S72_97G_wg7QqKASVtHDAffp53gA9LRVVpaVmvjB-XhjQ-aV3s2EYcTov6WT0ntYrjWWhmmJ1mI4gsF9W5hSMUE27prGSPqOKGvC9v779aPvsqcfIvUUOz4URt8lmWZXuDqE2Yio1bgAyIphNrWYWkcgwliriWNiARN2LlqbFPscRHJ-kz4EElw1zJDBHeuZIEZCn6z0nDfLHmdQj5N-aElG7_RfV4oNsjQDs1a7ICq4cV8wILdJUJCxmXEcOEl0dkG3kvmyuwK5tjxxmEEEwVICAPPEUaH3gAYxqL1HAa0Acrx7lVo8SrIbpL3cSJlurVcs_OhaQh-tl3ImdeKWrVkgjeM4QJSogoieZvWfvr5Tzjx65PPIawvjds_99m1weH0z35f5ktnePXIlRZbCSz7fI5nKxcvchDlzqB175KDk-b23_DVDWbUA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Profiling+of+the+fecal+microbiota+and+circulating+microRNA-16+in+IBS+subjects+with+Blastocystis+infection%C2%A0%3A+a+case%E2%80%93control+study&rft.jtitle=European+journal+of+medical+research&rft.au=Olyaiee%2C+Alireza&rft.au=Yadegar%2C+Abbas&rft.au=Mirsamadi%2C+Elnaz+Sadat&rft.au=Sadeghi%2C+Amir&rft.date=2023-11-06&rft.issn=2047-783X&rft.eissn=2047-783X&rft.volume=28&rft.issue=1&rft_id=info:doi/10.1186%2Fs40001-023-01441-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s40001_023_01441_8 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-783X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-783X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-783X&client=summon |